688266 泽璟制药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-2.448-23.293-46.775-32.053-39.380
总资产报酬率 ROA (%)-1.318-12.231-26.789-24.272-27.874
投入资产回报率 ROIC (%)-1.454-14.257-33.181-28.859-18.616

边际利润分析
销售毛利率 (%)93.39592.44191.34696.70799.901
营业利润率 (%)-42.149-77.058-160.618-241.145-1,102.018
息税前利润/营业总收入 (%)-48.580-81.244-165.924-262.516-1,250.446
净利润/营业总收入 (%)-41.231-76.373-160.601-242.693-1,123.157

收益指标分析
经营活动净收益/利润总额(%)111.115131.168107.252109.426111.604
价值变动净收益/利润总额(%)-6.549-4.910-1.349-2.752-4.028
营业外收支净额/利润总额(%)-0.0010.4350.4911.3120.002

偿债能力分析
流动比率 (X)2.2542.2201.7723.69111.851
速动比率 (X)2.1462.1231.6363.55511.687
资产负债率 (%)48.44343.03052.79728.23014.145
带息债务/全部投入资本 (%)33.61732.74934.8248.893--
股东权益/带息债务 (%)166.552192.701165.078936.788-4,499.415
股东权益/负债合计 (%)105.961131.43086.183242.721580.470
利息保障倍数 (X)7.55421.10836.77014.4528.426

营运能力分析
应收账款周转天数 (天)88.61788.55990.121117.9520.000
存货周转天数 (天)1,518.7311,292.9411,038.1892,154.9960.000